While HER2 andEGFR remain the most widely explored target antigens for solid tumors(Figure 13A), Trop-2and Nectin-4 antigens have exhibited consistent and steady growthin the last five years (Figure 13B).286,287 For hematological malignancies,CD30, CD19, CD22, and CD33 are the most extensively examined withalmost triple the number of patents as compared to journal articles(Figure 13A), whileCD79B shows the fastest growth in number of documents over the lastfive years (Figure 13B). The gene discussed is NECTIN4; the disease is hematologic disorder.